|
DIPYRIDAMOLE MAY COUNTERACT THE ANTICHOLINESTERASE EFFECT OF CHOLINESTERASE INHIBITORS, THEREBY POTENTIALLY AGGRAVATING MYASTHENIA GRAVIS
|
DIPYRIDAMOLE MAY COUNTERACT THE ANTICHOLINESTERASE EFFECT OF CHOLINESTERASE INHIBITORS, THEREBY POTENTIALLY AGGRAVATING MYASTHENIA GRAVIS
|
DIPYRIDAMOLE MAY COUNTERACT THE ANTICHOLINESTERASE EFFECT OF CHOLINESTERASE INHIBITORS, THEREBY POTENTIALLY AGGRAVATING MYASTHENIA GRAVIS
|
DIPYRIDAMOLE MAY COUNTERACT THE ANTICHOLINESTERASE EFFECT OF CHOLINESTERASE INHIBITORS, THEREBY POTENTIALLY AGGRAVATING MYASTHENIA GRAVIS
|
DIPYRIDAMOLE MAY COUNTERACT THE ANTICHOLINESTERASE EFFECT OF CHOLINESTERASE INHIBITORS, THEREBY POTENTIALLY AGGRAVATING MYASTHENIA GRAVIS
|
DIPYRIDAMOLE MAY COUNTERACT THE ANTICHOLINESTERASE EFFECT OF CHOLINESTERASE INHIBITORS, THEREBY POTENTIALLY AGGRAVATING MYASTHENIA GRAVIS
|
DIPYRIDAMOLE MAY COUNTERACT THE ANTICHOLINESTERASE EFFECT OF CHOLINESTERASE INHIBITORS, THEREBY POTENTIALLY AGGRAVATING MYASTHENIA GRAVIS
|
DIPYRIDAMOLE MAY COUNTERACT THE ANTICHOLINESTERASE EFFECT OF CHOLINESTERASE INHIBITORS, THEREBY POTENTIALLY AGGRAVATING MYASTHENIA GRAVIS
|
DIPYRIDAMOLE MAY COUNTERACT THE ANTICHOLINESTERASE EFFECT OF CHOLINESTERASE INHIBITORS, THEREBY POTENTIALLY AGGRAVATING MYASTHENIA GRAVIS
|
DIPYRIDAMOLE MAY COUNTERACT THE ANTICHOLINESTERASE EFFECT OF CHOLINESTERASE INHIBITORS, THEREBY POTENTIALLY AGGRAVATING MYASTHENIA GRAVIS
|
DIPYRIDAMOLE MAY COUNTERACT THE ANTICHOLINESTERASE EFFECT OF CHOLINESTERASE INHIBITORS, THEREBY POTENTIALLY AGGRAVATING MYASTHENIA GRAVIS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
BETABLOCKERS MAY REDUCE THE EFFECTIVENESS OF TREATMENT WITH PARASYMPATHOMIMETICS IN MYASTHENIA PTS. IN PTS RECIEVING BETABLOCKERS IT HAS PROLONGED BRADYCARDIA EFFECT
|
|
CONCURRENT USE MAY SOMETIMES CAUSE SEVERE AND FATAL SIDE EFFECTS
|
CONCURRENT USE MAY SOMETIMES CAUSE SEVERE AND FATAL SIDE EFFECTS
|
CONCURRENT USE MAY SOMETIMES CAUSE SEVERE AND FATAL SIDE EFFECTS
|
PARASYMPATHOMIMETICS EFFECTIVENESS IN MYASTHENIA GRAVIS IS REDUCED BY SOME BETABLOCKERS, ANTIARRHYTHMICS & GENERAL ANAESTHETICS
|
PARASYMPATHOMIMETICS EFFECTIVENESS IN MYASTHENIA GRAVIS IS REDUCED BY SOME BETABLOCKERS, ANTIARRHYTHMICS & GENERAL ANAESTHETICS
|
PARASYMPATHOMIMETICS EFFECTIVENESS IN MYASTHENIA GRAVIS IS REDUCED BY SOME BETABLOCKERS, ANTIARRHYTHMICS & GENERAL ANAESTHETICS
|
ANTICHOLINESTERASES MAY INHIBIT THE METABOLISM OF THE DRUG LEADING TO ITS INCREASED PLASMA LEVELS & TOXICITY
|
ANTICHOLINESTERASES MAY INHIBIT THE METABOLISM OF THE DRUG LEADING TO ITS INCREASED PLASMA LEVELS & TOXICITY
|
ANTICHOLINESTERASES MAY INHIBIT THE METABOLISM OF THE DRUG LEADING TO ITS INCREASED PLASMA LEVELS & TOXICITY
|
ANTICHOLINESTERASES MAY INHIBIT THE METABOLISM OF THE DRUG LEADING TO ITS INCREASED PLASMA LEVELS & TOXICITY
|
ANTICHOLINESTERASES MAY INHIBIT THE METABOLISM OF THE DRUG LEADING TO ITS INCREASED PLASMA LEVELS & TOXICITY
|
ANTICHOLINESTERASES MAY INHIBIT THE METABOLISM OF THE DRUG LEADING TO ITS INCREASED PLASMA LEVELS & TOXICITY
|
ANTICHOLINESTERASES MAY INHIBIT THE METABOLISM OF THE DRUG LEADING TO ITS INCREASED PLASMA LEVELS & TOXICITY
|
HALOTHANE MAY REDUCE THE EFFECTTIVENESS OF PARASYMPATHOMIMETICS
|
COLISTIN HAS SOME NEUROMUSCULAR BLOCKING ACTION & ANATGONISE NEOSTIGMINE ACTION
|
PARASYMPATHOMIMETICS MAY COUNTERACT EACH OTHER EFFECTS
|
CO-ADMINISTRATION MAY LEAD TO INCREASED PARASYMPHATHOMIMETIC EFFECT CAUSING BRADYCARDIA, HYPOTENSION, A-V CONDUCTION ABNORMALITIES, FLUSHING, DIARRHOEA, ABDOMINAL PAIN, INCREASED SALIVATION ETC
|
ECHOTHIOPATE IODIDE POTENTIATES THE EFFECT OF OTHER CHOLINESTERASE INHIBITORS CAUSING INCREASED CHOLINERGIC SIDE EFFECTS
|